Advertisement
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/aptuit/42018/
(Photo: http://www.newscom.com/cgi-bin/prnh/20100114/MM37675 )
Advertisement
"The complexities of drug development are driving the need for integrated development organizations that provide exceptional pharmaceutical services, delivered on time, in full and at a best-in-class cost," stated Timothy C. Tyson, chairman and chief executive officer at Aptuit. "We are committed to helping companies tackle some of today's toughest challenges with the ultimate goal of enhancing drug development productivity and increasing the flow of products to the market for our clients."
Mr. Tyson's presentation, to be delivered on Thursday, January 14, 2010, at 11:30 a.m., outlines Aptuit's strategy, business objectives, strength of financial position, and differentiated business model as an integrated drug development organization. The company's priorities for 2010 are focused on the following three core areas:
Demonstrated Commitment to Scientific Excellence
Industry-Leading Customer Service
Continued Nurturing of Talent
"The demand for outsourced clinical services is growing and Aptuit is well positioned to take a leadership role in this evolving market," commented Thierry Amat, chief financial officer at Aptuit. "The continued strong support of Welsh, Carson, Anderson & Stowe and Temasek Holdings has been critical to Aptuit's achievements and has enabled us to build a strong foundation for continued success in the coming years."
About Aptuit
Aptuit, Inc. is a global pharmaceutical services company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality, and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's largest private equity investors. For more information about Aptuit please visit www.aptuit.com.
-- Continuing to advance the company's world-class centers of excellence for solid-state chemistry and active pharmaceutical ingredient development -- Enhancing proven integrated programs such as Aptuit INDiGO(TM), a proprietary platform designed to speed the time required to advance a molecule from discovery into first-in-man studies
SOURCE Aptuit, Inc.
